Navigation Links
Cornerstone Therapeutics Announces Management Change
Date:5/19/2009

important factors that could cause our actual results or events to differ materially from those indicated by such forward-looking statements, including risks relating to our ability to develop and maintain the necessary sales, marketing, supply chain, distribution and manufacturing capabilities to commercialize our products, including difficulties relating to the manufacture of ZYFLO CR(R) tablets; the possibility that the Food and Drug Administration (the FDA) will take enforcement action against us or one or more of our marketed drugs that do not have FDA-approved marketing applications; patient, physician and third-party payor acceptance of our products as safe and effective therapeutic products; our ability to maintain regulatory approvals to market and sell our products that do have FDA approved marketing applications; our ability to enter into additional strategic licensing, collaboration or co-promotion transactions on favorable terms, if at all; our ability to maintain compliance with NASDAQ listing requirements; adverse side effects experienced by patients taking our products; difficulties relating to clinical trials, including difficulties or delays in the completion of patient enrollment, data collection or data analysis; the results of preclinical studies and clinical trials with respect to our products under development and whether such results will be indicative of results obtained in later clinical trials; our ability to satisfy FDA and other regulatory requirements; our ability to obtain, maintain and enforce patent and other intellectual property protection for our products and product candidates; and the other factors described in Item 1A (Risk Factors) of our Quarterly Report on Form 10Q filed with the Securities and Exchange Commission (the SEC) on May 7, 2009 and other filings that we make with the SEC. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements
'/>"/>
SOURCE Cornerstone Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cornerstone Therapeutics Reports First Quarter 2009 Financial Results
2. Cornerstone Therapeutics Announces $70 Million Strategic Transaction With Chiesi Farmaceutici SpA
3. Cornerstone Therapeutics to Host First Quarter 2009 Conference Call
4. OnCore(r) 9.0 Released: 'Top 5' Priorities and Collaborative Initiatives Cornerstones of Product Development
5. Cornerstone Therapeutics Announces New Board of Directors
6. Cornerstone BioPharma Announces Completion of Merger with Critical Therapeutics
7. Cornerstone Therapeutics, Inc. Taps Josh Franklin to Head Marketing Team
8. Carnegie Mellons Tepper School of Business to Host 2008 Cornerstones Symposium on Building City of the Future, March 25
9. Prospect Therapeutics, Inc.s GCS-100 Exhibits a Low Toxicity Profile in Cancer Patients
10. Fate Therapeutics Adds Pratik Multani, M.D., M.S., as Vice President Clinical Development to Advance Upcoming Clinical Programs of Stem Cell Modulators
11. ImQuest BioSciences and Arisyn Therapeutics Introduce Novel New HCV Therapeutic Agent at Hepatitis Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... identified the first genetic variant specifically associated with ... for around 10-15 per cent of all breast ... the breast cancer sub-type, called invasive lobular carcinoma, ... of this particular kind of breast cancer, which ... published today (Thursday) in the journal PloS ...
(Date:4/17/2014)... PLOS Pathogens , children who live in regions of ... immune response to infection with malaria parasites that may ... and illness and partially control the growth of malaria ... develop future interventions that prevent or mitigate the disease ... 200 million cases of malaria occur worldwide, resulting in ...
(Date:4/17/2014)... AURORA, Colo. (April 17, 2014) Two recent ... Medicine researcher and colleagues may help scientists develop ... virus, Yellow fever, Japanese encephalitis and other disease-causing ... of biochemistry and molecular genetics at the School ... the Howard Hughes Medical Institute, and colleagues recently ...
(Date:4/17/2014)... University synthetic biology team has created a new ... therapeutics that could travel the body and selectively ... Engineering cell-based, biological devices that monitor and modify ... synthetic biology. However, no existing technology enabled bioengineers ... physiological state and respond in a customized fashion. ...
(Date:4/17/2014)... many as 10 million older Americans suffer from depression, ... , However, new research a project that followed ... six years found that Internet use among the ... than 30 percent. , "That,s a very strong effect," ... telecommunication, information studies and media who led the project. ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2Health News:Internet use can help ward off depression among elderly 2
... initiate a range of care management programs for people living ... room (ER) use, improved health and lower costs. The ... (ACHP), are part of a report that is a comprehensive ... to improve care. Care management is the coordination ...
... Factors for,Developing MS, UB Study Shows, Summary: ... (CCSVI), which has attracted global attention as possibly being correlated ... the presence of risk factors in subjects who do not ... of 252 volunteers has found an association between CCSVI and ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, ... fiddling with food and drink or doing some last-minute grooming, ... admit to being dangerously distracted while behind the wheel, a ... Interactive/HealthDay poll, most adults who drive on a regular ...
... or respirators put health care workers at risk of 2009 ... in the U.S., according to a study published in the ... the journal of the Society of Healthcare Epidemiology of America. ... Disease Control and Prevention (CDC), tracked 63 Southern California health ...
... , WEDNESDAY, Nov. 30 (HealthDay News) -- Women with lobular ... other forms of breast cancer to have a father who ... Swedish researchers examined the family history, pathology reports and hospital ... 2008. About 40 percent of the women had invasive ductal ...
... , WEDNESDAY, Nov. 30 (HealthDay News) -- About 40 percent ... before high school, which suggests that suicidal thoughts and behavior ... new study. As part of an ongoing survey, University ... or 19, about their history of suicide attempts. Nearly ...
Cached Medicine News:Health News:New report: Community health plans improving care for patients with chronic illnesses 2Health News:New report: Community health plans improving care for patients with chronic illnesses 3Health News:Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows 2Health News:Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows 3Health News:Risk factors for CCSVI are similar to risk factors for developing MS, UB study shows 4Health News:Most U.S. Drivers Engage in 'Distracting' Behaviors: Poll 2Health News:Most U.S. Drivers Engage in 'Distracting' Behaviors: Poll 3Health News:Most U.S. Drivers Engage in 'Distracting' Behaviors: Poll 4Health News:Lobular Breast Cancer Linked to Paternal Cancer History 2Health News:Many Suicidal Teens Make First Try Before High School 2
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that it expects revenues for the fourth quarter ... full-year 2013 revenues to approximately $208 million. ...
(Date:1/14/2014)... N.J. , Jan. 14, 2014 InformEx, ... and sellers of high-value chemistry, will hold the 30 th ... Miami Beach Convention Center from January 21-24. ... 3,500 attendees from top pharmaceutical, fine chemical and specialty chemical ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
Breaking Medicine Technology:HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... Inc. (OTC BB: NSPR) ("Inspire" or the "Company"), the developer ... protective stent system, today announced another positive study, reinforcing MGuard,s ... evaluation by Drs. Dmitry Dratva, Yaron Almagor, Jonathan Balkin, David ... Department of Cardiology at Shaare Zedek Medical ...
... SpeechTrans, a leader in app-based multi-language translation, ... Impaired. The new app enables the hearing impaired to ... Italian and German and Mandarin Chinese without the need ... With the new app, each person can simply speak ...
Cached Medicine Technology:Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization 2Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization 3Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization 4Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization 5Israeli Facility Study Demonstrates MGuard™ Stent System Helps Prevent Distal Embolization 6SpeechTrans Offers Mobile Translation App for Hearing Impaired 2
... & Lomb PMMA Anterior Chamber Intraocular Lenses ... aphakia in patients 60 years of age ... been removed by primary intracapsular cataract extraction; ... is a structural reason that the anterior ...
... STAARVISC II is a sterile nonpyrogenic, transparent ... STAARVISC II contains 12 mg/ml of high ... sodium hyaluronate dissolved in physiological saline. In ... viscosity is 105,000 cps (105 Pa s) ...
... Methylcellulose solution that is especially well suited ... incision surgery. The low molecular weight of ... minimal risk of elevated intraocular pressure. The ... of the surgical field throughout capsulorhexis and ...
... AMO Vitrax features a low ... protection and viscosity you need ... phaco and small-incision surgery. The ... anterior chamber depth for safe, ...
Medicine Products: